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Abstract: Selective cytopheretic inhibitory device (SCD)
therapy is an immunomodulatory treatment provided by a
synthetic biomimetic membrane in an extracorporeal
circuit, which has shown promise in preclinical large animal
models of severe sepsis as well as in clinical trials treating
patients with acute kidney injury and multiple organ
failure. During SCD therapy, citrate is administered to
lower ionized calcium levels in blood for anticoagulation
and inhibition of leukocyte activation. Historically, citrate
has been known to interfere with sorbent dialysis, there-
fore, posing a potential issue for the use of SCD therapy
with a portable dialysis system. This sorbent dialysis SCD
(sorbent SCD) would be well suited for battlefield and
natural disaster applications where the water supply for
standard dialysis is limited, and the types of injuries in
those settings would benefit from SCD therapy. In order to
explore the compatibility of sorbent and SCD technologies,
a uremic porcine model was tested with the Allient sorbent
dialysis system (Renal Solutions Incorporated, Fresenius
Medical Care, Warrendale, PA, USA) and concurrent SCD
therapy with regional citrate anticoagulation. The hypoth-
esis to be assessed was whether the citrate load required by
the SCD could be metabolized prior to recirculation from
systemic blood back into the therapeutic circuit. Despite
the fact that the sorbent SCD maintained urea clearance
without any adverse hematologic events, citrate load for
SCD therapy caused an interaction with the sorbent
column resulting in elevated, potentially toxic aluminum
levels in dialysate and in systemic blood. Alternative strat-
egies to implement sorbent-SCD therapy will be required,
including development of alternate urease-sorbent column
binding chemistry or further changes to the sorbent-SCD
therapeutic circuit along with determining the minimum
citrate concentration required for efficacious SCD
treatment. Key Words: Sorbent dialysis—Citrate—Cyto-
pheresis—Immunomodulation.
Systemic inflammatory response syndrome from
either sepsis or acute organ failure is a leading cause
of death in critically ill patients in the United States
(1,2). Despite prompt treatment with antibiotics, fluid
resuscitation, and artificial organ function support,
mortality rates still exceed 30% (3,4). Selective
cytopheretic inhibitory device (SCD) therapy is an
immunomodulatory treatment recently reported to
improve survival time in a preclinical large animal
model of severe sepsis (5) and in clinical trials treat-
ing patients with acute kidney injury and multiple
organ dysfunction syndrome (MODS) (6–8). The
SCD is composed of a synthetic biomimetic mem-
brane that mimics the environment of capillary beds
where leukocyte extravasation may occur in order to
bind and sequester leukocytes from the systemic cir-
culation in an extracorporeal blood circuit. The low-
velocity, low-shear blood flow path around bundles of
polysulfone fibers reproduces capillary shear condi-
tions to bind activated leukocytes during a systemic
inflammatory disease state. To further minimize the
systemic effects of activated leukocytes, the blood is
anticoagulated with regional citrate infusion to lower
blood ionized calcium (iCa) levels to 0.2–0.5 mM,
which inhibit the coagulation system of the blood.
This lowering of blood iCa also has an inhibitory
effect on neutrophil (NE) activation (9), thereby
simultaneously combining the SCD effect to seques-
ter activated circulating leukocytes and limit the
potential activation of leukocytes entering the SCD
and the low-iCa environment.
doi:10.1111/j.1525-1594.2012.01541.x
Received April 2012; revised June 2012.
Address correspondence and reprint requests to Dr. David
Humes, Innovative BioTherapies, Inc., 401 W. Morgan Rd., Ann
Arbor, MI 48108, USA. E-mail: dhumes@innbio.com
bs_bs_banner
© 2012, Copyright the Authors
Artificial Organs © 2012, International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc.
Artificial Organs 2013, 37(2):203–210
Battlefield injuries, earthquakes, tsunami, explo-
sions, and other causes of building collapse have the
potential to produce many cases of attendant acute
renal failure (ARF) in areas where access to purified
water for dialysis may not be available (10,11). Por-
table sorbent dialysis systems have been developed,
requiring as little as 6 L of tap water to regenerate
dialysate, making dialysis treatment available at new
sites including field hospitals (12–14). For a review of
sorbent technologies, see Agar (12).A promising syn-
ergistic approach to treat sepsis, ARF, and MODS in
water scarce settings is to combine SCD and portable
sorbent dialysis therapies. In this sorbent dialysis-
SCD (sorbent-SCD) treatment, the immunomodula-
tory properties of the SCD would be leveraged to
counteract the progression of sepsis, ARF, or MODS,
while the sorbent dialysis system would be used for
small solute clearance, for removal of toxins, and to
provide an extracorporeal platform for the SCD
therapy.
Optimal SCD therapy is dependent on the admin-
istration of citrate, which is currently thought to
modulate leukocyte adhesion to the polysulfone
hollow fibers of the SCD, as well as modulate NE
release from noncirculating pools (5). Heparin is the
preferred anticoagulation therapy during sorbent
dialysis because previous studies have shown that
citrate can interact with sorbent columns, resulting in
the release of aluminum complexes (15). High alumi-
num blood levels may thereby occur (16–18). An
approach to integrate the two potentially incompat-
ible therapies into a combined sorbent dialysis-SCD
therapy is to use systemic heparin coagulation for
sorbent compatibility and regional citrate adminis-
tration within the SCD extracorporeal circuit in
order to attempt to isolate the citrate from the
sorbent column. The working hypothesis being that
the citrate administered postsorbent column would
not be exposed to the sorbent column during the first
pass of circulation, avoiding citrate-sorbent column
interactions, and furthermore that citrate would be
metabolized in the body prior to blood recirculation
into the therapeutic circuit.
MATERIALS AND METHODS
Porcine model of uremia
A uremic state was achieved via bilateral renal
artery ligation with the organs left in situ, along with
administration of a urea load in a porcine model. All
procedures were approved by the University Com-
mittee for Use and Care of Animals at the University
of Michigan.
Pigs (60 kg) were placed under general anesthesia
using xylazine hydrochloride (2.2 mg/kg i.m.) and
Telazol (Phoenix Pharmaceutical Inc., Burlingame,
CA, USA) (6 mg/kg i.m.), then intubated and main-
tained on isoflurane (2–4%) with the balance oxygen
for the duration of the study period. A catheter was
placed into the right carotid artery and the right
external jugular vein provided access for drug admin-
istration and blood pressure monitoring. An 11-Fr
20-cm Brevia short-term hemodialysis catheter was
inserted into the left external jugular vein using a
modified Seldinger technique and connected to the
hemodialysis circuit. The renal pedicle was then
approached via ventral midline laparotomy for bilat-
eral renal artery ligation with the organs left in situ.
Urea was administered intravenously to achieve
elevated blood urea-nitrogen (BUN) levels required
by the Allient sorbent system (Renal Solutions Incor-
porated, Fresenius Medical Care, Warrendale, PA,
USA), which was designed to remove urea and other
low molecular weight toxins from uremic patients
(14). A 10% urea solution in 5% dextrose in water
was administered intravenously to achieve systemic
BUN >75 mg/dL at the beginning of the study, simu-
lating a uremic condition. The premixture and infu-
sate were calculated according to total body water,
starting BUN, and anticipated urea clearance by the
Allient system in order to maintain higher than
normal BUN throughout a 6-h study.
Following systemic heparinization (100 U/kg i.v.),
6 h of hemodialysis was administered using the
Allient sorbent system connected in series with
the SCD. Six liters of tap water was used to create the
dialysate, which was regenerated throughout the
study. Citrate regional anticoagulation was achieved
with anticoagulation citrate dextrose-A (ACD-A,
Baxter, Deerfield, IL, USA), which was infused into
the blood line pre-SCD while 2% CaCl2 was infused
into the venous return post-SCD to compensate for
iCa bound by citrate. Arterial electrolytes, BUN,
creatinine, and citrate levels were monitored in the
systemic circulation, in dialysate, and at various loca-
tions in blood circuit. Dialysate was tested hourly to
detect ammonia breakthrough. Blood samples were
collected systemically and in the extracorporeal
circuit, which was sampled presorbent, postsorbent,
pre-SCD, and post-SCD to determine efficacy and
compatibility of the sorbent-SCD treatment.
SCD
The SCD is a column with an inlet and outlet for
flow, containing porous polysulfone hollow fibers
with an inner diameter of 200 mm, a wall thickness of
40 mm, and a molecular weight cutoff of 40–50 kDa
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(5). Blood flow is directed to the extracapillary space
(ECS) of the SCD. SCD used for these studies had a
calculated outer membrane surface area of 0.98 m2
and was supplied by CytoPherx, Inc. (Ann Arbor, MI,
USA).
Allient sorbent dialysis system
An Allient sorbent dialysis system was utilized
with either SORB+ or HISORB+ sorbent columns
(Renal Solutions Incorporated). SORB+ columns
have an approximate total urea-nitrogen capacity of
9.5–23.5 g, which were used in studies 1–5, while
HISORB+ columns have a total urea-nitrogen capac-
ity of 23.5–35.0 g, which were used for studies 6 and 7.
Extracorporeal circuit design
Two extracorporeal circuit designs were evaluated
in a pilot study, with the sorbent dialysis system and
SCD either in parallel or in series. In the sorbent-SCD
parallel circuit configuration, blood was perfused at a
rate of 300 mL/min, divided in parallel circuits such
that 200 mL/min was diverted to the sorbent system
and 100 mL/min to the SCD system (Fig. 1). This
circuit was maintained over a 6-h time course.
At the end of the pilot study, the circuit was altered
to run in series with the SCD following the sorbent
dialysis (Fig. 2). Citrate was infused into the blood
line pre-SCD with 2% calcium chloride being infused
into the venous return post-SCD to compensate for
the ionized calcium bound by the citrate.
Pressure measurements in both circuits were
assessed with a Mesa Labs 90XL (Mesa Labs, Lake-
wood, CO, USA) at various locations including pre-
sorbent and postsorbent system, as well as pre- and
post-SCD.
Assessment of sorbent-SCD efficacy
and compatibility
In six additional studies in the porcine model of
uremia, the series sorbent-SCD setup was utilized. In
order to assess sorbent cartridge efficacy in removing
uremic waste, samples were collected presorbent and
postsorbent cartridge and assayed for urea nitrogen
to determine urea clearance. Postcartridge ultrafil-
trate was also analyzed for ammonia breakthrough,
an indication of cartridge exhaustion.
SCD efficacy was assessed by complete blood
count (CBC), manual differentials, NE apoptotic
state, NE activation state, and quantification of leu-
kocyte binding to SCD cartridge to determine if the
SCD remained effective during sorbent dialysis com-
pared with historical SCD-citrate values.
Compatibility of the sorbent dialysis and SCD
systems was assessed by sampling of the blood
outflow, prior to entering the sorbent cartridge
(presorbent), to determine if there are detectable
levels of citrate in the blood returning to the sorbent
system, which might interact with the sorbent
column. In addition, presorbent and postsorbent
dialysate was assessed for aluminum levels, as well as
systemic blood levels of aluminum, to assess possible
aluminum complex formation and to monitor the
porcine model for possible aluminum toxicity.
Regional citrate anticoagulation
ACD-A was infused pre-SCD to maintain the iCa
concentration in the circuit between 0.2 and 0.5 mM.
Calcium chloride (2% concentration) was infused to
maintain systemic iCa values between 1.1 and
1.3 mM. These iCa levels were monitored utilizing an
i-STAT System (Abbott Point of Care, Inc., Prince-
ton, NJ, USA).
Analyte quantification
Dialysate ammonia was detected through the use
of dip sticks supplied by Renal Solutions Incorpo-
rated to estimate concentration by color change via
2- and 5-mg indicators. BUN was measured by
i-STAT analyzer with 6+ cartridges.FIG. 1. Sorbent-SCD parallel circuit configuration.
FIG. 2. Sorbent-SCD series circuit configuration.
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Citrate analysis
A citrate analysis kit (#K655-100, BioVision,
Mountain View, CA, USA) was used according to the
manufacturer’s instructions to determine concentra-
tion of citrate by colorimetry. The colored product
was quantified using a SpectraMax M5 multimode
microplate reader (MTX Lab Systems, Vienna, VA,
USA) at a wavelength of 570 nm.
Aluminum analysis
Presorbent and postsorbent system dialysate
samples were stored in an ultralow freezer at -80°C
until batched samples were ready for analysis. Sys-
temic blood samples were collected in ethylenedi-
aminetetraacetic acid tubes and sent fresh for
analysis. Initial baseline and end of study samples
were shipped to Spectra Laboratories (Milpitas, CA,
USA) for heavy metal analysis consisting of alumi-
num, antimony, arsenic, barium, beryllium, cadmium,
calcium, chloride, chromium, copper, fluoride, lead,
magnesium, mercury, nitrate, potassium, selenium,
silver, sodium, sulfate, thallium, and zinc. Based on
this preliminary screening where most heavy metal
concentrations remained low and unchanged, all sub-
sequent samples were analyzed for aluminum
content alone, due to the known possible interaction
of the aluminum within the sorbent column with
citrate.
Leukocyte analysis
Automated CBCs were measured with a Hemavet
950 (Drew Scientific, Waterbury, CT, USA). Total
manual white cell counts were determined using the
Unopette system (BD Biosciences, San Jose, CA,
USA) and differentials were determined from blood
smears after ethanol fixation and Wright stain
(Richard-Allen Scientific, Kalamazoo, MI, USA). NE
activation was assessed by CD11b expression. Briefly,
fluorescein isothiocyanate conjugated antiporcine
CD11b antibody (AbD SeroTec, Raleigh, NC, USA)
was added to prechilled peripheral blood. Red cells
were then lysed and the leukocytes fixed by addition
of fluorescence-activated cell sorting lyse solution
(Becton,Dickinson and Company,Franklin Lakes,NJ,
USA). Cells were collected by centrifugation and
resuspended for flow-cytometry analysis. CD11b
expression was quantitatively assessed as a mean fluo-
rescent intensity with a flow cytometer (Accuri, Ann
Arbor, MI, USA).
SCD elution
SCD elution was performed by a previously estab-
lished method (5). Briefly, at the end of each experi-
ment, the circuit was disconnected and normal saline
was flushed continuously through the ECS of the
SCD until fluid was free of visible blood. Fluid was
drained from the device and a stabilization buffer
containing a calcium chelating agent was added.
Adherent cells were then mechanically removed
from the cartridge eluent for analysis.
RESULTS
Extracorporeal circuit selection: sorbent-SCD
series configuration
The sorbent-SCD series extracorporeal circuit con-
figuration allowed for a lower total blood flow rate
(only 200 mL/min) and the resultant pre- and post-
SCD pressures were lower than in the parallel circuit
configuration. Due to the lower pressures and lower
blood flow rates of the series circuit, it was selected for
use in subsequent studies, as low flow rates and low
pressures are desirable in the clinical setting, as they
would have less negative impact on severely ill
patients.
Assessment of sorbent SCD in a porcine model
of uremia
Efficacious sorbent dialysis during sorbent-SCD
therapy
The sorbent-SCD series circuit (Fig. 2) was used in
the subsequent uremic porcine studies (n = 6), with
careful measurements to determine compatibility of
sorbent system with SCD treatment with regional
citrate administration. Dialysate ammonia (Table 1)
and systemic BUN (Table 2) were measured as
markers of sorbent dialysis efficacy.Ammonia release
from the sorbent cartridge was used as one measure of
sorbent system failure, in addition to samples being
TABLE 1. Dialysate ammonia (mg/dL) summary for
sorbent-SCD porcine studies: study 1 (parallel circuit) and
studies 2–7 (series circuit)
Time course
4 h 5 h 6 h
Study 1 0 0 0
Study 2 0 0 1
Study 3 0 0 0
Study 4 1 4 4
Study 5 0 1 4
Study 6 0 0 0
Study 7 0 0 0
Studies 1–5 utilized SORB+ sorbent columns and studies 6 and
7 utilized HISORB+ columns. Note that for all studies, t = 0–3 h, all
ammonia measurements were 0 mg/dL. For study 4, ammonia
breakthrough occurred at t = 4 h, and for study 5, ammonia break-
through occurred at t = 5 h.
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taken for assessment of any heavy metal bleed-off
from the sorbent cartridge.Study 2 had a trace amount
of ammonia in the last hour of study. Studies 4 and 5
had trace amounts of ammonia at hour 4, which
increased to 4 mg/dL at last hour (Table 1). This may
have been caused by the high serum BUN (over
100 mg/dL) (Table 2) and lower ammonia binding
capacity of the SORB+ cartridges used. In the last two
studies, 6 and 7, the sorbent cartridge was switched to
the HISORB+, which had a higher ammonia binding
capacity. For both of these studies, no ammonia was
detected throughout the time course.
In the sorbent-SCD parallel circuit (pilot, study 1),
serum BUN levels declined throughout the study and
no ammonia was detected from the sorbent cartridge
ultrafiltrate during the 6-h treatment. In the subse-
quent sorbent-SCD series studies, the decrease in
BUN values over time (Table 2) indicates that urease
in the sorbent cartridge was not negatively affected
by the circuit citrate levels required for effective SCD
therapy and that the sorbent dialysis system was
efficacious.
SCD treatment during sorbent-SCD therapy
The SCD was demonstrated to function in the
sorbent-SCD series circuit with regional citrate
administration with no adverse cardiovascular or
immunological events, such as leukopenia, in studies
to date. Briefly, in this uremic porcine model with
renal artery ligation, because no pathogens were
administered, no major impact was shown in NE
quantification throughout the time course of the
study (Fig. 3A). Furthermore, activation as assessed
by CD11b expression in isolated NE demonstrated
no statistical difference in activation status over the
duration of the sorbent-SCD treatment (P > 0.05)
(Fig. 3B). SCD elution after 6 h of sorbent-SCD
treatment resulted in a total recovery of 3.5 
0.9 ¥ 109 cells.
Assessment of the compatibility of
sorbent-SCD therapy
Citrate concentrations were measured for all
studies in various circuit locations to assess regional
citrate administration for the SCD. Of critical impor-
TABLE 2. Systemic BUN (mg/dL) summary for sorbent-SCD porcine studies:
study 1 (parallel circuit) and studies 2–7 (series circuit)
Time course
0 h 0.25 h 0.5 h 1 h 2 h 3 h 4 h 5 h 6 h
Study 1 101 55 — 39 49 37 35 26 24
Study 2 100 100 — 57 46 41 33 27 23
Study 3 98 82 72 69 58 49 41 36 31
Study 4 120 94 64 76 59 50 40 33 27
Study 5 98 82 72 69 58 49 41 36 31
Study 6 79 79 — 49 45 36 30 21 21
Study 7 106 — 66 54 42 35 28 23 19
Studies 1–5 utilized SORB+ sorbent columns and studies 6 and 7 utilized HISORB+
columns.
FIG. 3. Total neutrophils in systemic circulation during the sorbent-SCD porcine study were reported as average  standard error (S.E.),
n = 6 (A), and neutrophil activation as assessed by CD11b expression was also reported as average  S.E., n = 6 (B). MFI, mean
fluorescence intensity.
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tance, presorbent and postsorbent dialysate samples
were measured to verify low citrate concentration.
The citrate concentrations in both the presorbent and
postsorbent dialysate were higher than expected and
continued to increase throughout the duration of the
sorbent-SCD therapy, from 0 mM when the circuit
was initially started to an average of approximately
7 mM after 6 h of therapy, which was statistically sig-
nificant (P < 0.05, n = 3, Fig. 4). Presorbent and post-
sorbent dialysate citrate concentrations were not
significantly different (P > 0.05, n = 3).
In order to assess if the increasing citrate concen-
trations within the sorbent system led to an interac-
tion with the sorbent cartridge, a heavy metal panel
analysis was carried out. Of the heavy metals ana-
lyzed, the only metal with measurable values that
changed significantly from t = 0 h to t = 6 h in a
selected study was aluminum. The analysis of studies
5–7 for aluminum found that presorbent and postsor-
bent dialysate samples showed statistically significant
increases in aluminum levels at all times after 2 h of
therapy (P < 0.05, n = 3, Fig. 5A), regardless of the
occurrence or absence of ammonia breakthrough.
To assess if increased aluminum levels in dialysate
also led to higher aluminum levels in systemic blood,
further heavy metal analysis was conducted. Serum
aluminum levels increased significantly over the
duration of the study, from 31.4  7.6 to final values
of 406.5  78.4 mg/L (P < 0.05, n = 3, Fig. 5B).
DISCUSSION
Sorbent-SCD therapy is a promising approach to
treat sepsis, ARF, and MODS by combining existing
SCD and portable sorbent dialysis technologies. The
immunomodulatory properties of the SCD with
regional citrate anticoagulation, which has previously
been shown to reduce circulating levels of activated
NE, could be leveraged to counteract the progression
of sepsis,ARF, or MODS, while the concurrent use of
sorbent dialysis system would provide small toxin
clearance using only 6 L of tap water, which would be
especially helpful in care settings where purified
water is not available.
In uremic porcine studies with conventional citrate
anticoagulation protocol for SCD treatment (5),
citrate was administered pre-SCD at a rate sufficient
to maintain iCa between 0.2 and 0.5 mM. In the
studies described in this report under similar regional
citrate anticoagulation conditions, both presorbent
dialysate and postsorbent dialysate citrate and
aluminum levels increased over time, suggesting
incomplete first pass citrate metabolism, citrate accu-
mulation, and that citrate-sorbent column interaction
occurred, releasing aluminum. Furthermore, similar
concentrations of citrate presorbent and postsorbent
suggest a well-mixed circuit that equilibrates over
time; therefore, attempting to regionally isolate sec-
tions of the circuit by regional administration of
citrate was not effective. Assessment of ammonia
release from the sorbent cartridge was not necessar-
ily an indicator of the start of sorbent column break-
down or correlative with released aluminum. For
example, ammonia breakthrough occurred in study 5
at hour 4, but the initial rise in aluminum levels
occurred even earlier, at t = 2 h. In the last two
FIG. 4. Sorbent dialysate citrate levels presorbent (gray) and
postsorbent (black) (average  standard error).
FIG. 5. Aluminum in presorbent dialysate
(gray) and in postsorbent dialysate (black)
(average  standard error [S.E.], n = 3)
(A), and systemic serum aluminum
(average  S.E., n = 3) (B) in the sorbent-
SCD series circuit.
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sorbent uremic porcine studies (studies 6 and 7), the
sorbent cartridge was switched to HISORB+, with a
high ammonia binding capacity, and no ammonia
release was detected; however, high aluminum levels
persisted, suggesting release of aluminum from
sorbent column filler materials.
Systemic aluminum levels found in this porcine
model were indicative of a potentially toxic
concentration. Briefly, the Association for the
Advancement of Medical Instrumentation standards
suggest a maximum aluminum concentration of
10 mg/L in water for hemodialysis and the minimum
serum concentration associated with dialysis alumi-
num toxicity to be 0.06 mg/L (19) or 60 mg/L. The
suggested maximum aluminum level in dialysate has
been specified to prevent accumulation of this toxic
metal in the patient (20). Aluminum toxicity is a
serious and potentially fatal disease state. Uptake of
aluminum from the dialysate is associated with bone
disease (18), anemia (17), and the dialysis encephal-
opathy syndrome, which is usually fatal (16).
However, aluminum toxicity in patients on chronic
dialysis for end-stage renal disease may be com-
pletely different from toxicity associated with ARF
patients in an intensive care unit setting treated a few
times with sorbent-SCD therapy.
All sorbent column technologies currently employ
aluminum chemistry to immobilize urease. Results in
this report suggest that SCD therapy with the current
level of regional citrate anticoagulation and sorbent
dialysis are currently incompatible technologies due
to the interaction of citrate and the sorbent column.
Although the cause of aluminum displacement from
the sorbent column was not directly evaluated in
this study, previous studies have investigated citrate’s
interaction with these types of sorbent columns.
Citrate interaction with aluminum-containing
sorbent cartridges is three pronged (15): (i) citrate
uncouples urease from alumina, which is the material
holding the urease enzyme in place within the car-
tridge; (ii) citrate complexes with the aluminum,
forming a soluble complex which can be released
from the cartridge; and (iii) citrate competes with the
released urease for binding to the hydrated zirco-
nium oxide, therefore the urease circulates in the
dialysate, which breaks down urea, releasing
ammonia. Changes to sorbent column urease immo-
bilization chemistry could correct these issues.
Citrate is rapidly metabolized to bicarbonate by
the liver. Therefore, a simple working hypothesis
that was tested for sorbent-SCD combined therapy
was that citrate entering the systemic circulation
from the extracorporeal circuit would be quickly
metabolized and would not result in systemic accu-
mulation and citrate exposure to the sorbent system
upon recirculation. However, the literature suggests
that an infusion of 0.5 mmol/kg/h citrate solution is
not able to be fully eliminated from the body (21).
The infusion rate in our porcine model was approxi-
mately 0.97 mmol/kg/h to meet the required amount
for SCD therapy, exceeding the metabolic capability
of the average animal tested. These results suggest
that a strategy that needs to be developed to miti-
gate citrate-aluminum interactions is critical to suc-
cessful implementation of sorbent systems and SCD
therapy.
CONCLUSIONS
Regional citrate anticoagulation required for
optimal SCD therapy is currently incompatible
with sorbent dialysis technology due to an inability
to exclude citrate from interacting with sorbent
columns containing aluminum. The strategy
employed attempted to isolate and eliminate citrate
by systemic metabolism prior to blood recirculation
into the therapeutic circuit. However, citrate was
not fully eliminated by liver metabolism, leading to
increasing systemic concentrations and therefore
presorbent concentration, allowing for aluminum-
citrate complex formation. Aluminum liberated from
sorbent columns led to increased aluminum levels
in dialysate and then in systemic blood, causing
potential aluminum toxicity. This study confirms
that sorbent-SCD therapy maintains urea clearance
while avoiding hematologic adverse reactions. Thus,
sorbent-SCD combined therapy remains promising
as an approach to sepsis, ARF, and MODS treatment
where purified water for dialysis is not available.
Alternate strategies to implement sorbent-SCD
therapy in order to eliminate citrate interaction with
sorbent columns will be required, including develop-
ment of alternate urease-sorbent column binding
chemistry or further changes to the sorbent-SCD
therapeutic circuit and determining minimum
citrate concentration required for efficacious SCD
treatment.
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